首页> 外文OA文献 >Colchicine for children with pericarditis: systematic review of clinical studies
【2h】

Colchicine for children with pericarditis: systematic review of clinical studies

机译:秋水仙碱治疗小儿心包炎的临床研究综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE: To review the evidence for the efficacy and safety of colchicine in children with pericarditis. DESIGN: Systematic review. SEARCH STRATEGY: The following databases were searched for studies about colchicine in children with pericarditis (June 2015): Cochrane Central, Medline, EMBASE and LILACS. ELIGIBILITY CRITERIA: All observational and experimental studies on humans with any length of follow-up and no limitations on language or publication status were included. The outcomes studied were recurrences of pericarditis and adverse events. DATA EXTRACTION: Two authors extracted data and assessed quality of included studies using the Cochrane risk of bias tool for non-randomised trials. RESULTS: Two case series and nine case reports reported the use of colchicine in a total of 86 children with pericarditis. Five articles including 74 paediatric patients were in favour of colchicine in preventing further pericarditis recurrences. Six studies including 12 patients showed that colchicine did not prevent recurrences of pericarditis. LIMITATIONS: No randomised controlled trials (RCTs) were found. CONCLUSIONS: Although colchicine is an established treatment for pericarditis in adults, it is not routinely used in children. There is not enough evidence to support or discourage the use of colchicine in children with pericarditis. Further research in the form of large double-blind RCTs is needed to establish the efficacy of colchicine in children with pericarditis.
机译:目的:探讨秋水仙碱治疗儿童心包炎的疗效和安全性的证据。设计:系统评价。搜索策略:在以下数据库中搜索了有关心包炎儿童中秋水仙碱的研究(2015年6月):Cochrane Central,Medline,EMBASE和LILACS。资格标准:包括对人类的所有观察性和实验性研究,随访时间不限,对语言或出版状态无限制。研究的结果是心包炎的复发和不良事件。数据提取:两位作者使用Cochrane偏倚风险工具对非随机试验进行了提取,并评估了纳入研究的质量。结果:两个病例系列和九个病例报告报告了总共86例心包炎患儿使用秋水仙碱。五篇文章(包括74名儿科患者)赞成秋水仙碱预防进一步的心包炎复发。包括12例患者在内的6项研究表明秋水仙碱不能预防心包炎的复发。局限性:未发现随机对照试验(RCT)。结论:尽管秋水仙碱是成人心包炎的既定治疗方法,但并未在儿童中常规使用。没有足够的证据支持或阻止心包炎患儿使用秋水仙碱。为了确定秋水仙碱在患有心包炎的儿童中的疗效,需要以大型双盲RCT形式进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号